TWi Pharmaceuticals, Inc.

Climate Impact & Sustainability Data (2018)

Established Employee Welfare Committees at the Company and Synpac-Kingdom Pharma, providing various employee welfare activities.

Established an Audit Committee composed of three Independent Directors in 2016.
Established a spokesperson/acting spokesperson system for information disclosure and communication.

Short-term Goals:

Continue to focus on innovative special generic drugs and maintain the momentum of around 3-5 ANDA filings with the U.S. FDA per year.
Expand the technical platform to non-oral products such as local/percutaneous absorption preparations and special generic drug products such as eye drugs.
Enter the international market outside the United States and Greater China region to become one of the global integrated pharmaceutical companies.

Market competition and insufficient economies of scale resulted in operating losses despite a slight increase in operating revenue.
Continuous investment in R&D of high-tech special generic drugs in the US market resulted in high R&D expenditures.
Litigation-related expenses from a lawsuit with a brand pharmaceutical manufacturer delayed the launch of generic drugs.
Subsidiary Synpac-Kingdom Pharmaceuticals, Inc. could not fully utilize its capacity due to ongoing eye drug development.
Subsidiary TWi Biotechnology, Inc. continued to invest in new drug development, increasing R&D expenses.

Continued to focus on innovative special generic drugs and maintained a filing momentum of around 3-5 ANDA submissions with the U.S. FDA per year.
Expanded the technical platform to non-oral products such as local/percutaneous absorption preparations and special generic drug products such as eye drugs.
Integrated and strengthened the internal senior and professional R&D team.
Expanded the scope of dosage forms and product portfolio.
Enhanced global outreach through drug licensing, co-marketing, and strategic alliances.

Climate Change Data